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Objective: To compare efficacy of indacaterol to that of fixed-dose combination (FDC) 
  formoterol and budesonide (FOR/BUD) and FDC salmeterol and fluticasone (SAL/FP) for the 
treatment of chronic obstructive pulmonary disease (COPD) based on the available randomized 
clinical trials (RCTs).
Methods: Fifteen placebo-controlled RCTs were included that evaluated: indacaterol 150 µg 
(n = 5 studies), indacaterol 300 µg (n = 4), FOR/BUD 9/160 µg (n = 2), FOR/BUD 9/320 µg 
(n = 3), SAL/FP 50/500 µg (n = 5), and SAL/FP 50/250 µg (n = 1). Outcomes of interest were 
trough forced expiratory volume in 1 second (FEV1), total scores for St. George’s Respiratory 
Questionnaire (SGRQ), and transition dyspnea index (TDI). All trials were analyzed simul-
taneously using a Bayesian network meta-analysis and relative treatment effects between all 
regimens were obtained. Treatment-by-covariate interactions were included where possible to 
improve the similarity of the trials.
Results: Indacaterol 150 µg resulted in a higher change from baseline (CFB) in FEV1 at 12 weeks 
compared to FOR/BUD 9/160 µg (difference in CFB 0.11 L [95% credible intervals: 0.08, 0.13]) 
and FOR/BUD 9/320 µg (0.09 L [0.06, 0.11]) and was comparable to SAL/FP 50/250 µg (0.02 L 
[−0.04, 0.08]) and SAL/FP 50/500 µg (0.03 L [0.00, 0.06]). Similar results were observed for 
indacaterol 300 µg at 12 weeks and indacaterol 150/300 µg at 6 months. Indacaterol 150 µg 
demonstrated comparable improvement in SGRQ total score at 6 months versus FOR/BUD 
(both doses), and SAL/FP 50/500 µg (−2.16 point improvement [−4.96, 0.95]). Indacaterol 
150 and 300 µg demonstrated comparable TDI scores versus SAL/FP 50/250 µg (0.21 points 
(−0.57, 0.99); 0.39 [−0.39, 1.17], respectively) and SAL/FP 50/500 µg at 6 months.
Conclusion: Indacaterol monotherapy is expected to be at least as good as FOR/BUD (9/320 
and 9/160 µg) and comparable to SAL/FP (50/250 and 50/500 µg) in terms of lung func-
tion. Indacaterol is also expected to be comparable to FOR/BUD (9/320 and 9/160 µg) and 
SAL/FP 50/500 µg in terms of health status and to SAL/FP (50/250 and 50/500 µg) in terms 
of breathlessness.
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Introduction
Chronic obstructive pulmonary disease (COPD) is a disorder characterized 
by the   progressive development of airway obstruction, which manifests as an International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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  accelerated decline in lung function, with symptoms such 
as   breathlessness on physical exertion, deteriorating health 
status, and exacerbations.1
Treatments aim to prevent and control symptoms, reduce 
exacerbations, improve health status, and increase exercise 
tolerance. Currently, the Global Initiative for Chronic Obstruc-
tive Lung Disease recommend initiation with a short-acting 
bronchodilator followed by the addition of long-acting bron-
chodilators as the disease progresses.1 Commonly used bron-
chodilators include inhaled long-acting β2-agonists (LABAs) 
(eg, formoterol or salmeterol), the inhaled long-acting anti-
cholinergic tiotropium, and oral methylxanthines.1 If a patient 
with severe disease experiences repeated exacerbations, an 
inhaled steroid may be added and fixed-dose   combinations 
(FDC) of LABA plus an inhaled steroid, including formoterol/
budesonide (FOR/BUD) or salmeterol/fluticasone proprionate 
(SAL/FP), may be   prescribed.1 Despite recommendations, 
it has been found that a high percentage of patients receive 
FDCs as a   first-line treatment.2
Indacaterol is a novel once-daily inhaled LABA indicated 
for maintenance bronchodilator treatment of airflow obstruc-
tion in adult patients with COPD. The recommended dose 
is one 150 microgram (µg) capsule once a day, using the 
Onbrez® Breezhaler® (Novartis) inhaler, increased on medical 
advice to a maximum dose of one 300 µg capsule once a day.3 
In an extensive phase III clinical trial program indacaterol 
demonstrated superior lung function to LABA monotherapies 
and was at least as good as LABAs with respect to other 
outcomes.4–7 Given these findings, and the knowledge of the 
early use of FDCs, a comparison of   indacaterol to FDCs is a 
relevant clinical question.
In the absence of a head-to-head randomized controlled 
trial (RCT) for the comparison of interest, the objective of 
the current study was to indirectly compare the efficacy of 
indacaterol 150 µg, indacaterol 300 µg, fixed-dose FOR/
BUD, and fixed-dose SAL/FP for the treatment of COPD 
patients based on the currently available RCT evidence by 
means of a network meta-analysis. Outcomes of interest 
were lung function measured by trough forced expiratory 
volume in 1 second (FEV1), health status measured by the 
St. George’s Respiratory Questionnaire (SGRQ) total score, 
and breathlessness as assessed by transition dyspnea index 
(TDI) total score.
Methods
Identification and selection of studies
A systematic literature search was performed using a pre-
defined search strategy in MEDLINE® and EMBASE®; study 
documents for indacaterol studies were provided by   Novartis. 
Search terms included a combination of free-text and 
  thesaurus terms relevant to COPD, indacaterol, salmeterol, 
formoterol, and RCTs (see Appendix for search strategy). 
The search strategy was initially performed for the period 
1989–2009 and a supplementary search was undertaken for 
the period 2009–2010 in order to capture the most recent 
literature.
Two reviewers independently evaluated each identified 
study against the following predetermined criteria:
•	 Population of interest: adults with COPD.
•	 Interventions: indacaterol 150 µg or 300 µg, fixed dose 
combinations of FOR/BUD and SAL/FP.
•	 Comparators: comparators included any of the interven-
tions or placebo. Studies that solely evaluated different 
components of the fixed dose combination separately 
were excluded.
•	 Outcomes: outcomes of interest included trough FEV1 
(reported predose values) at 12 weeks and 6 months, 
SGRQ total score at 6 months, and TDI total score at 
6 months.
•	 Study design: RCTs.
For the studies identified that met the selection criteria, 
details were extracted on study design, population char-
acteristics, interventions, and the outcomes trough FEV1 
at 12 weeks and 6 months, SGRQ total score at 6 months, 
and TDI total score at 6 months. Only outcomes that were 
within 2 weeks of the time point of interest were extracted. 
For each outcome the difference in the change from baseline 
(CFB) (or difference at follow-up adjusted for baseline) was 
extracted where reported. In cases where the difference in 
CFB was not reported, it was calculated by subtracting the 
CFB in the placebo from the CFB in the active treatment (or 
the adjusted CFB values). If the CFB values per treatment 
were not reported they were extracted from figures using 
the software DigitizIt version 1.5.8. The standard error of 
the difference in CFB was extracted where available or 
calculated based on the uncertainty or variation reported 
(eg, 95% confidence interval or standard deviation). If there 
was insufficient information to calculate the standard error 
of the difference, an average standard deviation was calcu-
lated from the studies included in each specific analysis and 
combined with the study-specific sample size to derive the 
standard error.
Analysis
Bayesian network meta-analysis models were used8–10 to ana-
lyze the created data set for the CFB in FEV1 at 12 weeks and International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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at 6 months, the CFB in SGRQ total score at 6 months, and 
the TDI total score at 6 months, to simultaneously synthesize 
the results of the included studies and to obtain differences 
for indacaterol 150 and 300 µg versus FOR/BUD, SAL/FP, 
and placebo.
Network meta-analyses within the Bayesian framework 
involve data, a likelihood distribution, a model with param-
eters, and prior distributions.10 The model relates the data 
from the individual studies to basic parameters reflecting the 
(pooled) relative treatment effect of each intervention com-
pared to an overall reference treatment, eg, placebo. Based on 
these basic parameters, the relative efficacy between each of 
the competing interventions was obtained. For all endpoints 
a regression model with a normal likelihood distribution 
was used.9,10 For each outcome, a fixed and a random effects 
model was evaluated. The fixed effects model assumes that 
the differences in true relative treatment effects across studies 
in the network of evidence are caused only by the differ-
ences in treatment comparisons. The random effects model 
assumes that differences in observed treatment effects across 
the studies in the network are not only caused by the different 
treatment comparisons, but that there is also heterogeneity 
in the relative effects for a particular type of comparison 
caused by factors that modify that relative treatment effect. 
A comparison of the fit of the fixed and random effects model 
to the data based on the residual deviance was used to select 
a fixed or random effects model.11
With a network meta-analysis, randomization only holds 
within a trial and not across trials. As a result, there is the risk 
that patients who were studied in different comparisons are 
not similar, which leads to consistency violations. In order to 
minimize confounding bias, treatment by covariate interac-
tions were incorporated in the models.12 Covariates potentially 
causing bias were selected based on clinical expertise and 
evaluation of whether these covariates were effect modifiers 
of any of the treatments under evaluation in individual studies 
analyzed. The following covariates were included simultane-
ously where possible and otherwise in separate models where 
insufficient data were available: 1) Proportion of patients 
who are current smokers (as opposed to ex-smokers); and 2) 
Proportion of patients with severe or very severe COPD (as 
opposed to mild or moderate COPD). Additional analyses 
were also performed, including study level covariates for age, 
and sex; which were not presented given the limited impact 
of the treatment by covariate interactions.
The results of the network meta-analysis provide rela-
tive treatment effects of each treatment versus a competing 
intervention, eg, differences in TDI or the differences in 
the CFB for FEV1 or SGRQ. In order to transform these 
relative estimates into absolute expected results with each 
treatment (eg, TDI or CFB in FEV1 or SGRQ), the relative 
treatment effects of each regimen relative to placebo were 
combined with absolute average treatment effect for placebo 
as a reference.
The Bayesian approach involves a formal combination 
of a prior probability distribution, with a likelihood distri-
bution for the model parameters to obtain a posterior prob-
ability distribution for the estimates of the basic   parameters. 
In order to avoid prior beliefs influencing the results of 
the model,   noninformative prior distributions were used. 
Prior distributions of the relative treatment effects were 
  normal   distributions with mean 0 and a variance of 106. 
A uniform distribution with range of 0 to 2 was used for 
the prior distribution of heterogeneity for the random effects 
models. The posterior distribution can be interpreted in terms 
of probabilities and permits calculation of the probability that 
each treatment is best out of those compared given the data 
at hand; this gives the Bayesian approach an advantage over 
the frequentist approach.
WinBUGS 1.4.1 statistical software was used for the 
analyses.13 Summary statistics are presented for the expected 
absolute and relative treatment effects. In addition to point 
estimates reflecting the most likely value, 95% credible 
intervals (95% CrI) reflecting the range of true underlying 
effects with 95% probability are presented. Furthermore, 
for each of the endpoints, the probability that indacaterol 
is better than a certain regimen is presented. Results are 
presented without adjustment for covariates for the CFB in 
FEV1 at 12 weeks and 6 months, CFB in SGRQ total score 
at 6 months, and TDI total score at 6 months. Results with 
adjustment are discussed for FEV1 at 12 weeks. The inclusion 
of covariates was explored for SGRQ and TDI, but was not 
always feasible given the data limitations.
Results
Study selection and characteristics
The literature search identified 411 potentially relevant stud-
ies (Figure 1). The first review excluded 375 (91%) of these 
abstracts because of the trial design (117, 28%), interven-
tion (107, 26%), trial duration (60, 15%), duplication (47, 
11%), comparator (24, 6%), and population (20, 5%). The 
full text review of 36 remaining studies excluded 25 (69%) 
studies, largely because of study design. Overall, 11 studies 
were identified from the search4,6,14–22 and 4 relevant RCTs 
for indacaterol were added from its clinical trial program 
(Novartis studies B2335S,23 B2336,24 B1302,25 and B233326). International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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411 abstracts identified through
Medline and EMBASE and screened
using PICOS
References excluded: (375)
Trial design out of scope (117)
Patient pop. out of scope (20)
Intervention out of scope (107)
Comparison out of scope (24)
Outcomes out of scope (0)
Trial duration <6 weeks (60)
Repeat abstracts (47)
References excluded: (25)
Trial design out of scope (8)
Patient pop. out of scope (1)
Indacaterol CSRs excluded (2)
Comparison out of scope (2)
(B2349 and B2350)
Intervention out of scope (0)
Comparison out of scope (7)
Outcomes out of scope (7)
Repeat paper (1)
Abstract only (1)
36 abstracts selected for full text 
review
Indacaterol CSRs (8):
All studies: Excluding Asian studies:
Reference excluded (3)
15 trials included in analysis
B2334 (Dahl et al4)
B2335S
B2336
B2346 (Feldman et al6)
B2333
B1302
B2349
B2350
12 trials included in analysis
Patient pop. out of scope (Asian) (3)
15 trials included
(corresponding to 17 study documents):
9 FDCs trials + 6 indacaterol trials
(11 publications + 6 CSRs)
Figure 1 Flow diagram of study selection.
Abbreviations: CSR, complete study reports; FDC, fixed-dose combinations; PICOS, patients, interventions, comparators, outcomes, and study design.
Data on file were used for studies B233427 and B2346,28 
which   corresponded to publications by Dahl et al 20104 and 
Feldman et al 2010,6 respectively.
The network of evidence (Figure 2) illustrates that all 
active therapies were compared to placebo, and that 3 studies 
directly compared indacaterol 150 µg to indacaterol 300 µg. 
Study B2334 evaluated indacaterol 300 µg and 600 µg once 
daily compared to placebo and formoterol 12 µg twice daily 
over 52 weeks. This was the first pivotal indacaterol regis-
tration study, and in addition to data on the 300 µg dose, 
it provides safety data on the 600 µg dose – a dose that is 
2 to 4 times the EU-approved dose. B2335S was an adaptive 
seamless design study that combined an initial dose-selection 
phase with a pivotal registration phase and assessed inda-
caterol 150 µg and 300 µg once daily compared to placebo 
and open-label tiotropium 18 µg once daily over 26 weeks. 
B2346 evaluated indacaterol 150 µg once daily compared to 
placebo over 12 weeks, and was the third indacaterol pivotal 
registration study (providing the required replicate data for the 
150 µg dose), while B2336 compared indacaterol 150 µg once 
daily to placebo as well as salmeterol 50 µg twice daily over 
26 weeks, providing additional data on the 150 µg dose.International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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Placebo 
(no 
Concomitant
ICS use)
FDC
Salmeterol/
Fluticasone
50/500 µg BID
FDC
Formoterol/
Budesonide
9/320 µg BID
FOR/BUD 9/320 µg
Calverley et al17
Tashkin et al21
Rennard et al20
SAL/FP 50/500µg
Barnes et al14
Calverley et al15
Calverley et al16
Mahler et al19
Zheng et al22 (Asian)a
SAL/FP 50/250 µg
Hanania et al18
FDC
Salmeterol/ 
Fluticasone
50/250 µg BID
FDC
Formoterol/
Budesonide
9/160 µg BID
FOR/BUD 9/160 µg
Tashkin et al21
Rennard et al20
Indacaterol
300 µg OD
Indacaterol
150 µg OD
Placebo 
(No ICS)
No ICS subgroup:
Dahl et al4 (34)
No ICS subgroup:
Feldman et al6 (46)
Kornmann et al7 (36)
No ICS subgroup:
Donohue et al5 (35S)
B2333 (Asian)a
B1302 (Asian)a
Figure 2 Network of studies.
Note: aStudies included predominantly Asian patients.
Abbreviations: BID, twice daily; FDC, fixed-dose combinations; FOR/BUD, FDC formoterol and budesonide; ICS, inhaled corticosteroids; OD, once daily; SAL/FP, 
FDC salmeterol and fluticasone proprionate.
Tables 1 and 2 present the details of the study and patient 
characteristics for the 15 studies included in the analysis. All 
studies were multicenter placebo-controlled RCTs with a 
parallel design and included a total of 10,211 adult patients 
with COPD. The studies included patients $40 years of age 
with FEV1/FVC of #0.70 and FEV1 percent predicted ,80%, 
while the indacaterol trials required patients to have a pre-
dicted FEV1 of at least 30%. Most studies included patients 
who were current or ex-smokers with a smoking history of at 
least 10 years, although some studies included patients with 
a smoking history of at least 20 pack-years  (Hanania et al 
2003,18 Mahler et al 2002,19 B2334,4 B2335S,5 B2336,7 and 
B23466). Three studies included predominantly Asian patients 
(Zheng et al 2007,22 and studies B130223 and B233324), 
whereas the remaining studies included mostly Caucasian 
patients or reported study centers in Europe and North Amer-
ica. Limited information was reported on the comorbidities 
of the patients, although most studies excluded patients with 
asthma or other respiratory or pulmonary diseases and other 
clinically significant diseases that may have affected treat-
ment. Some differences across the studies were observed in 
baseline FEV1 and health status (as assessed by SGRQ total 
score), which may have been related to COPD severity.
Comparative efficacy
In Table 3 the individual study results for the different end-
points are presented. These study findings were synthesized in 
2 series of network meta-analyses: the first analyses included 
all studies and the second analyses excluded the 3 Asian 
studies. As patients using background inhaled corticoster-
oids (ICS) were permitted entry into the indacaterol studies 
  (providing they continued to use ICS at a stable dose and 
regimen throughout the study), only data for patients not using 
ICS (‘non-ICS users’) were included in the analyses in order 
to ensure the patients in the placebo arms of the indacaterol 
trials were sufficiently similar to those in the FDC studies. 
Therefore, the analysis was based on unpublished subgroup 
data provided by Novartis for all indacaterol studies.
Trough Fev1 at 12 weeks and 6 months
All treatments were more efficacious than placebo at 12 weeks 
and 6 months in terms of trough FEV1 for all   analyses without International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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covariates (Table 4). In the analysis including all studies 
(without covariates), indacaterol 150 µg resulted in higher 
FEV1 compared to both FOR/BUD 9/160 µg and FOR/
BUD 9/320 µg at both time points (see Table 5). Results 
for indacaterol 300 µg were similar to indacaterol 150 µg, 
demonstrating a more favorable FEV1 improvement than both 
doses of FOR/BUD (see Table 6). In comparison to SAL/FP 
50/500 µg, indacaterol 150 µg and 300 µg were comparable 
in terms of FEV1 at both time points. This was also the case 
for indacaterol 150 µg and 300 µg versus SAL/FP 50/250 µg 
at 12 weeks and at 6 months. The results were not sensitive 
to the exclusion of the 3 Asian studies, and only minor differ-
ences between the 2 analyses were observed in FEV1 results 
(≈0.01 L associated with indacaterol 150 µg and 300 µg) in 
most cases (see Tables 5 and 6).
Figure 3 illustrates the impact of adjusting for differences 
in the proportion of current smokers and patients with severe 
or very severe COPD on the relative results of indacaterol 
150 µg versus the alternatives for FEV1 at 12 weeks for 
both scenarios (all studies included and 3 Asian studies 
excluded). Indacaterol 150 µg was more efficacious than 
FOR/BUD 9/160 µg in most of the scenarios. The increase 
associated with indacaterol 150 µg in comparison to FOR/
BUD 9/320 µg varied from 0.09 L (95% CrI: to −0.02, 0.21) 
to 0.10 L (95% CrI: 0.02, 0.17) and was most sensitive to 
the proportion of patients with severe COPD (where the 
credible internals included zero). Indacaterol 150 µg and 
300 µg remained comparable to SAL/FP 50/500 µg. Again, 
the lowest relative benefits associated with indacaterol were 
observed when adjusted for severity or both severity and 
smoking status.
SGRQ total score at 6 months
In the scenario with all studies included (without covariates), 
all active treatments were more efficacious than placebo, with 
the exception of FOR/BUD 9/160 µg which included zero in 
the credible intervals (see Table 4). No data were available 
for SAL/FP 50/250 µg for SGRQ at 6 months. When the 
3 Asian studies were excluded from the analysis, SAL/FP 
50/500 µg was no longer more efficacious than placebo (as 
the CrI included zero). Based on the analysis of all studies 
without covariates, indacaterol 150 µg resulted in comparable 
improvement in SGRQ total score versus SAL/FP 50/500 µg, 
FOR/BUD 9/160 µg and FOR/BUD 9/320 µg, showing 
a trend towards better scores (2.16 points, 1.48 points, 
and 0.39 points improvement, respectively) (see Table 5). 
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Table 4 Results of network meta-analysis: all treatments versus placebo without covariates
Trough FEV1 L 
difference in 
CFB (95% CrI) 
at 12 weeks
Trough FEV1 L 
difference in 
CFB (95% CrI) 
at 6 months
SGRQ total score 
difference in 
CFB (95% CrI) 
at 6 months
TDI total score 
difference (95% CrI) 
at 6 months
All studies
IND 150 µg 0.17 (0.15, 0.20) 0.16 (0.13, 0.19) −4.43 (−6.67, −2.17) 1.01 (0.65, 1.37)
IND 300 µg 0.17 (0.15, 0.20) 0.16 (0.13, 0.19) −3.01 (−5.26, −0.81) 1.19 (0.83, 1.55)
SAL/FP 50/500 µg 0.14 (0.13, 0.16) 0.16 (0.13, 0.19) −2.27 (−4.33, −0.50) 1.70 (1.11, 2.29)
SAL/FP 50/250 µg 0.16 (0.10, 0.21) 0.16 (0.10, 0.22) NR 0.80 (0.11, 1.49)
FOR/BUD 9/320 µg 0.09 (0.07, 0.11) 0.08 (0.06, 0.10) −4.03 (−6.46, −1.60) NR
FOR/BUD 9/160 µg 0.07 (0.05, 0.09) 0.06 (0.04, 0.09) −2.95 (−6.33, 0.40) NR
All studies excluding 3 Asian studies
IND 150 µg 0.18 (0.16, 0.21) 0.18 (0.14, 0.21) −4.89 (−7.35, −2.47) 1.10 (0.67, 1.53)
IND 300 µg 0.17 (0.14, 0.21) 0.17 (0.14, 0.21) −3.20 (−5.67, −0.84) 1.26 (0.83, 1.69)
SAL/FP 50/500 µg 0.14 (0.12, 0.16) 0.15 (0.12, 0.18) −1.44 (−3.39, 0.58) 1.70 (1.10, 2.29)
SAL/FP 50/250 µg 0.16 (0.10, 0.21) 0.16 (0.10, 0.22) NR 0.80 (0.11, 1.49)
FOR/BUD 9/320 µg 0.09 (0.07, 0.11) 0.08 (0.06, 0.10) −4.02 (−6.25, −1.80) NR
FOR/BUD 9/160 µg 0.07 (0.05, 0.09) 0.06 (0.04, 0.09) −2.96 (−6.05, 0.13) NR
Abbreviations: CFB, change from baseline; CrI, 95% credibility interval; FEV1, forced expiratory volume in 1 second; FOR/BUD, fixed-dose formoterol and budesonide; 
IND, indacaterol; NR, not reported; SAL/FP, fixed-dose salmeterol and fluticasone proprionate; SGRQ, St. George’s Respiratory Questionnaire; TDI, Transition Dyspnea   
Index.
(see Table 6). As with FEV1, excluding the Asian studies 
had minimal impact on the results and improved the point 
estimates in favor of indacaterol.
TDI total score at 6 months
All treatments were more efficacious than placebo for TDI 
(see Table 4). Comparative estimates versus FOR/BUD were 
not possible at 6 months given the lack of data. Comparable 
results were observed for indacaterol and SAL/FP in the 
analyses without covariates (see Tables 5 and 6). Indacaterol 
150 µg and 300 µg demonstrated slightly higher TDI scores 
compared to SAL/FP 50/250 µg, with an improvement of 
0.21 points and 0.39 points, respectively. However, compared 
to SAL/FP 50/500 µg, indacaterol 150 µg and 300 µg had 
slightly lower TDI scores, with point estimates of −0.69 
points and −0.51 points, respectively. Consistent results were 
observed in the scenario without the Asian studies, although 
the point estimates improved slightly for indacaterol and the 
CrI widened, since the number of studies included in the 
analysis was reduced from 6 to 5.
Discussion
The objective of this study was to compare the efficacy of 
indacaterol 150 µg and 300 µg once daily versus fixed-dose 
combinations FOR/BUD and SAL/FP twice daily for COPD 
in terms of trough FEV1, SGRQ total score and TDI total 
score. In terms of trough FEV1, all treatments were better 
than placebo. At 12 weeks, indacaterol 150 and 300 µg 
were more efficacious than FOR/BUD 9/160 µg, at least 
as efficacious as FOR/BUD 9/320 µg, and comparable to 
SAL/FP (50/250 and 50/500 µg). Results were consistent at 
6 months and therefore both indacaterol doses are expected 
to be at least comparable to the fixed-dose combinations for 
this parameter. The probability that the FEV1 was higher for 
patients receiving indacaterol 150 or 300 than for each active 
comparator ranged from 51% to 99%. For SGRQ total score 
at 6 months, results suggest that indacaterol provides a com-
parable SGRQ improvement to the fixed-dose combinations 
for FOR/BUD (both doses) and SAL/FP 50/500 µg. In terms 
of TDI total score at 6 months, the results did support the 
efficacy of all treatments compared to placebo. Again, results 
indicate that indacaterol was comparable to both doses of 
SAL/FP for which data were available. Differences in SGRQ 
and TDI scores did not reach a clinically meaningful level 
(eg, less than SGRQ 4 points29 and less than TDI 1 points30), 
which suggests that indacaterol offers a comparable level of 
symptom relief to the fixed-dose combinations evaluated. As 
with previous analyses, improvements in TDI were more 
pronounced for indacaterol 300 µg compared to indacaterol 
150 µg. In a separate analysis of pooled data, this additional 
improvement with the 300 µg dose was particularly apparent 
in patients with severe COPD.3
Although RCTs form the basis of the network and allow 
for the indirect comparisons in the absence of head-to-head 
comparisons, the key question is whether the trials in the 
network are sufficiently similar to yield meaningful results. International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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Figure 3 Impact of adjustment for differences in effect-modifiers across studies: difference in indacaterol 150 µg versus alternatives for CFB in Fev1 at 12 weeks and 95% 
credible Intervals.
Abbreviations: CFB, change from baseline; Fev1, forced expiratory volume in 1 second; FOR/BUD 9/160, fixed-dose formoterol and budesonide 9/160 µg; FOR/BUD 9/320, 
fixed-dose formoterol and budesonide 9/320 µg; IND 150, indacaterol 150 µg; PLBO, placebo; SAL/FP 50/250, fixed-dose salmeterol and fluticasone proprionate 50/250 µg; 
SAL/FP 50/500, fixed-dose salmeterol and fluticasone proprionate 50/500 µg.
In a network meta-analysis of RCTs involving multiple 
treatment comparisons, the randomization holds only within 
the individual trials, and not across trials. If the trials differ 
among the direct comparisons for study and patient charac-
teristics, and these differences are modifiers of the relative 
treatment effects, then the estimate of the indirect and mixed 
comparisons is biased.12
In the indacaterol studies patients were allowed to con-
tinue receiving concurrent ICS, which was not the case in the 
FOR/BUD and SAL/FP studies. To avoid biased estimates 
of indacaterol versus FOR/BUD and SAL/FP a subgroup of 
patients who did not receive an ICS in indacaterol studies 
was evaluated in the network meta-analysis.
Differences were identified in terms of the proportion of 
males, the average age, the proportion of current smokers, and 
the proportion of patients with severe or very severe COPD 
in the indacaterol studies (subgroup) compared to the patients 
in the other studies. To evaluate the extent of the effect these 
differences in patient characteristics had on the relative effect 
estimates, meta-regression models were used. Although it 
was not feasible to include all of the covariates of interest 
simultaneously due to the limited amount of data, where pos-
sible the proportion of current smokers and the proportion 
of patients with severe or very severe COPD were included 
in one model. Results adjusted for the proportion of males 
and the average age had only a marginal impact on the effect 
estimates, and are therefore not believed to be a likely source 
of bias in the unadjusted analysis. Adjustment for smoking 
status and COPD severity had a greater impact on the relative 
effect estimates (see Figure 3), but the differences between 
adjusted and unadjusted models were not greater than the 
amount of uncertainty in the estimates. As such, adjusted 
and unadjusted models lead to the same interpretation of the 
findings. Although the meta-regression analyses suggest that 
the results of the network meta-analysis are not likely to be 
greatly affected by similarity and consistency violations, it 
was not possible to assess the similarity of the studies in terms 
of all patient characteristics. For example, limited informa-
tion was presented for the comorbidities of patients across 
the trials. Therefore, it has to be accepted that with aggregate 
level data there is the risk of residual confounding bias.
Since the studies did not consistently report the ethnicity 
of the patients or report subgroup data, it was not feasible 
to include a covariate to adjust for differences in ethnic-
ity. However, studies included a predominantly Caucasian 
population, and all studies were combined in the analysis. An 
additional analysis with 3 Asian studies excluded resulted in 
similar estimates and suggests that ethnicity is not a factor 
of importance in the current evidence base.
In conclusion, indacaterol monotherapy (150 µg and 
300 µg) (no concomitant ICS) is expected to be at least as 
good as FOR/BUD (9/320 and 9/160 µg) and comparable to International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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SAL/FP (50/250 and 50/500 µg) with respect to lung function 
(trough FEV1). Indacaterol monotherapy (150 and 300 µg) 
is also expected to provide comparable efficacy in terms of 
health status (SGRQ total score) versus FOR/BUD (9/320 
and 9/160 µg) and SAL/FP 50/500 µg, as well as similar 
improvements in breathlessness (TDI total score) as SAL/
FP (50/250 and 50/500 µg).
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Appendix
Search strategy
The search strategy was applied for the time period from 1989 to 2009 and 2009 to 2010
No. Database Search term
1 MEDLINE (COPD OR chronic ADJ obstructive ADJ pulmonary ADJ disease OR COAD OR chronic ADJ 
obstructive ADJ airway ADJ disease OR chronic ADJ obstructive ADJ lung ADJ disease OR chronic 
ADJ bronchitis OR emphysema).TI,AB. OR Pulmonary-Disease-Chronic-Obstructive#.DE.
2 MEDLINE (Formoterol OR eformoterol OR foradil OR oxis OR atimos ADJ modulite OR atock OR perforomist 
OR salmeterol OR serevent OR tiotropium OR spiriva OR Ba ADJ ‘679’ ADJ BR OR Indacaterol OR 
onbrez OR arcapta).TI,AB.
3 MEDLINE PT = CONTROLLED-CLINICAL-TRIAL OR PT = RANDOMIZED-CONTROLLED-TRIAL OR 
Clinical-Trials-As-Topic.DE. OR Controlled-Clinical-Trials-As-Topic.DE. OR Randomized-Controlled-
Trials-As-Topic.DE. OR Randomized-Controlled-Trials-As-Topic.DE. OR (randomized OR randomized 
OR randomly OR placebo).TI,AB. OR trial.TI,AB.
4 MEDLINE 3 AND HUMAN = YES AND ANIMAL = YeS
5 MEDLINE 3 AND ANIMAL = YeS
6 MEDLINE 3 NOT (4 OR 5)
7 MEDLINE 1 AND 2 AND 3 AND 6 AND LG = EN AND HUMAN = YES AND ADULT#
8 eMBASe (COPD OR chronic ADJ obstructive ADJ pulmonary ADJ disease OR COAD OR chronic ADJ 
obstructive ADJ airway ADJ disease OR chronic ADJ obstructive ADJ lung ADJ disease OR chronic 
ADJ bronchitis OR emphysema).TI,AB.
9 eMBASe Chronic-Obstructive-Lung-Disease#.DE.
10 eMBASe (Formoterol OR eformoterol OR foradil OR oxis OR atimos ADJ modulite OR atock OR perforomist 
OR salmeterol OR serevent OR tiotropium OR spiriva OR Ba ADJ ‘679’ ADJ BR OR Indacaterol OR 
onbrez OR arcapta).TI,AB.
11 eMBASe Controlled-Clinical-Trial.DE. OR Double-Blind-Procedure.DE. OR Controlled-Clinical-Trial.DE. OR 
Randomized-Controlled-Trial.DE. OR Randomized-Controlled-Trial.DE.
12 eMBASe (randomized OR randomized OR placebo OR randomly).TI,AB. OR trial.TI.
13 eMBASe (11 OR 12) AND HUMAN = YES AND ANIMAL = YeS
14 eMBASe (11 OR 12) AND ANIMAL = YeS
15 eMBASe (11 OR 12) NOT (13 OR 14)
16 eMBASe 8 OR 9
17 eMBASe 16 AND 15 AND 10 AND LG = EN AND HUMAN = YES AND ADULT = YeS
18 MEDLINE and EMBASE [all] combined sets 7, 17
19 MEDLINE and EMBASE [all] dropped duplicates from 18
20 MEDLINE and EMBASE [all] unique records from 18
21 Medline split set 20
22 eMBASe split set 20
Notes: .ab. indicates a search for a term in abstract; .pt. indicates a search for a publication type.